Aura Biosciences: A Strong Buy on Promising Cancer Treatments and Solid Financials
Aura Biosciences Reports Q1 Results
Aura Biosciences | 10-Q: Quarterly report
Aura Biosciences 1Q Loss/Shr 40c >AURA
Aura Biosciences 1Q Loss/Shr 40c >AURA
Press Release: Aura Biosciences Reports First Quarter 2024 Financial Results and Business Highlights
Aura Biosciences Reports First Quarter 2024 Financial Results and Business Highlights Continued Enrollment in Global Phase 3 CoMpass Trial in Small Choroidal Melanoma and Indeterminate Lesions Ongoi
Raj Parekh to Exit Board at Aura Biosciences' Meeting
Aura Biosciences Inc: A Buy Rating on Strong Pipeline and Financial Health
Analysts Conflicted on These Healthcare Names: Sanofi (OtherSNYNF), Molina Healthcare (MOH) and Aura Biosciences Inc (AURA)
Analysts Offer Insights on Healthcare Companies: Aura Biosciences Inc (AURA), Spectral AI (MDAI) and Pyxis Oncology (PYXS)
We're Not Very Worried About Aura Biosciences' (NASDAQ:AURA) Cash Burn Rate
Analysts Are Bullish on Top Healthcare Stocks: Aura Biosciences Inc (AURA), Altimmune (ALT)
Aura Biosciences Shares Rise Following Q4 Results
Aura Biosciences (AURA) shares were up more than 2% in recent Wednesday trading after the clinical-stage biotechnology company reported its Q4 results. Earlier, the company booked a Q4 net loss of $22
Aura Biosciences GAAP EPS of -$1.93
Aura Biosciences: A Strong Buy on Clinical Progress and Financial Stability
Recap: Aura Biosciences Q4 Earnings
Aura Biosciences (NASDAQ:AURA) reported its Q4 earnings results on Wednesday, March 27, 2024 at 07:00 AM.Here's what investors need to know about the announcement.EarningsAura Biosciences beat estimat
Aura Biosciences Inc Files For Mixed Shelf Offering Of Up To $350M
Aura Biosciences Inc Files For Mixed Shelf Offering Of Up To $350M
Aura Biosciences FY 2023 EPS $(1.93) Misses $(1.82) Estimate
Aura Biosciences (NASDAQ:AURA) reported quarterly losses of $(1.93) per share which missed the analyst consensus estimate of $(1.82) by 6.04 percent. This is a 1.53 percent increase over losses of $(1
Aura Biosciences Cash, Cash Equivalents as at Dec. 31 $226.2M>AURA
Aura Biosciences Cash, Cash Equivalents as at Dec. 31 $226.2M>AURA
Aura Biosciences Has a Strong Cash Position Into 2H 2026 >AURA
Aura Biosciences Has a Strong Cash Position Into 2H 2026 >AURA
Press Release: Aura Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights
Aura Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights Enrolling Patients in Global Phase 3 CoMpass Trial in Small Choroidal Melanoma and Indeterminate L
No Data